WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN XXXX - @entity675 -ASSOCIATED MYELOID NEOPLASM.

@entity675 @entity1 @entity1667 @entity1712 @entity75 @entity5441 @entity18053 @entity381 @entity4149 @entity2213 @entity479
INTRODUCTION: The @entity18053 - @entity675 -positive, @entity5441 ( @entity5441 ) is a new category of hematological entities. Various clinical symptoms may occur, with no specific characteristics in either the clinical picture or the neuroimaging findings, and this may give rise to a diagnostic dilemma. A report on a long follow-up period (10 years) in a case of @entity5441 that presented with neuropsychiatric symptoms appears to be unique. Besides the complexity of the diagnostic process, the successful treatment is discussed. CASE REPORT: The @entity5441 was diagnosed in a male @entity1 at the age of 33 years, with involvement of the central nervous system and the myocardium. After the onset of the clinical signs, the MRI indicated bilateral cerebral and cerebellar @entity75 involving the watershed areas, mainly in the parieto-occipital regions. High-dose intravenous @entity479 ( @entity1667 500 mg/day) alleviated the neurological symptoms within a few weeks, and the administration of @entity2213 (200 mg/day) resulted in an impressive regression of the @entity1712 and @entity381 within 6 weeks. During the follow-up, the @entity1 has continued to receive @entity2213 . The molecular remission has persisted, no new complaints have developed and the condition of the @entity1 has remained stable. CONCLUSION: The timely recognition of the @entity5441 and identification of the disease subtype which led to the administration of @entity2213 may be the key to successful treatment. The long stable follow-up period gives rise to a new dilemma in the treatment of the @entity5441 in these special cases: for how long should a @entity1 receive a @entity4149 kinase inhibitor, and may the treatment be suspended?
